The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial

The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial

Abstract Systemic inflammation and oxidative burden in patients with type 2 diabetes mellitus (T2DM) causes deleterious cardiovascular outcomes. We sought to investigate the clinical antioxidative and anti-inflammatory effects of empagliflozin. Platelet function, oxidant and antioxidant biomarkers a...

Full description

Bibliographic Details
Main Authors: Sepehr Gohari, Tara Reshadmanesh, Hadi Khodabandehloo, Amir Karbalaee-Hasani, Hassan Ahangar, Shahram Arsang-Jang, Faramarz Ismail-Beigi, Mohsen Dadashi, Samin Ghanbari, Homa Taheri, Mojtaba Fathi, Muhammad Javad Muhammadi, Reyhaneh Mahmoodian, Atieh Asgari, Mohammadreza Tayaranian, Mehdi Moharrami, Mahsa Mahjani, Bijan Ghobadian, Hossein Chiti, Sheida Gohari
Format: Article
Language:English
Published: BMC 2022-11-01
Series:Diabetology & Metabolic Syndrome
Subjects:
SGLT2 inhibitor
Empagliflozin
Randomized controlled trial
Coronary artery disease
Inflammation
Type 2 diabetes mellitus
Online Access:https://doi.org/10.1186/s13098-022-00951-5

Similar Items

Similar Items